(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF - 2To fix a patient's irregular heartbeat, doctors first tested its digital 'twin'
- 3Pick Your Number one breakfast food
- 4Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- 5Viable Correspondence: Building Solid Connections
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- Merz visit highlights new strategic, and strained, Germany-Israel bond
- Flu illness count nears 5 million, with New York City among the hardest hit
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- Careful Living: Embracing the Current Second
- First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- The Best 15 Applications for Efficiency and Association
- Brazilian cardinal orders a popular Catholic priest to go offline following right-wing attacks
- Home Mechanization Frameworks for Brilliant Residing
